



August 21, 2019

To: Federal Communications Commission  
445 12<sup>th</sup> Street SW  
Washington, DC 20554

From: Jarren Baldwin  
Company: Allergan PLC  
4410 Rosewood Dr  
Pleasanton, CA 94588

Subject: Limited Agency Agreement  
Allergan PLC  
FCC ID: 2AUA2-OCUTT20

To Whom It May Concern:

We, Allergan PLC, hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number 2AUA2-OCUTT20 under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is August 21, 2019. The Limited Agency Agreement expires on August 21, 2020, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

A handwritten signature in blue ink, appearing to read "J. Baldwin".

Jarren Baldwin  
Associate Director, Engineering